ABSTRACT
The role of inflammation in atherosclerosis and plaque vulnerability is well recognized.
However, it is only during recent years it has become evident that this inflammation is modulated by immune responses against plaque antigens such as oxidized LDL. Interestingly, both protective and pathogenic immune responses exist and experimental data from animal studies antigens have demonstrated athero-protective effects in experimental models and a first generation of such immune-modulatory therapies are now in early or about to enter into clinical testing. A challenge in the clinical development of these therapies is that our knowledge of the role of the immune system in atherosclerosis largely rests on data from animal models of the disease. It is therefore critical that more attention is given to the characterization and evaluation of immune biomarkers for cardiovascular risk.
Current therapies for prevention of cardiovascular disease rest almost exclusively on risk factor intervention. This approach has proven very successful and experience from randomized clinical trials has shown that up to 40% of cardiovascular events can be prevented by optimal medical risk factor intervention (1) . However, in spite of these encouraging results the majority of treated patients still receive insufficient protection. It is likely that to further improve the efficacy of cardiovascular prevention new treatments directly targeting the disease process in the arterial wall need to be developed. Such treatments will need to specifically target atherosclerotic plaque inflammation. In this review we will discuss evidence suggesting that this can be achieved by modulating immune responses against plaque antigens as well as the need of developing validated biomarkers that can be used to measure such immune responses.
The concept of the immune system as an attractive target for future cardiovascular therapies is primarily based on experimental studies demonstrating that inhibition of inflammatory mediators and induction of specific immune responses can reduce atherosclerosis burden (2-5). The proposed pleiotropic and anti-inflammatory effects of statins and the usefulness of the inflammatory marker high-sensitivity C-reactive protein (hsCRP) in risk prediction in humans reinforce this notion (6, 7) . On the other hand, the failures of non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 specific inhibitors have taught us that general anti-inflammatory treatment may not be a viable option for the treatment of atherosclerosis and the targeting of more specific immune responses will be needed (8, 9) . Therefore, CRP, predominantly secreted by the liver and adipose tissue in response to inflammatory stress, is a relatively crude marker for the evaluation of specific immune responses in the vascular wall. It has become increasingly clear that to truly understand the role of inflammation in atherosclerosis CRP will be insufficient and novel biomarkers assessing the complex role of the immune system in the disease need to be developed. There is today convincing evidence for presence of immune responses against plaque antigens in atherosclerosis and it has been proposed that disease progression occurs as a result of a loss of immune tolerance against these antigens in the plaque (10) . However, atherosclerosis is probably not an autoimmune disease in the classical sense but rather a state of local immune dysfunction resulting in an imbalance between naturally occurring autoimmunity and the regulatory immune cells that should control this autoimmunity. The circumstance that women, which generally are more prone to develop autoimmune diseases, suffer from cardiovascular disease at an older age than men also suggest that atherosclerosis is not a true autoimmune disease.
Atherosclerosis and the immune system
An impressive list, encompassing almost all aspects of the immune system, can be compiled when trying to summarize immune mechanisms that contribute to atherosclerosis development in mice (Fig. 1) . Depletion of monocytes, the precursors of macrophage foam cells in plaques, can to a large extent abrogate atherosclerosis development in mice (11, 12) . Interestingly, this effect is more prominent at early stages of the disease while depleting monocyte/macrophages from advanced lesions does not alter plaque size or composition (13) . Dendritic cells have been implicated in the formation of the earliest detectable plaques (14, 15) . Neutrophils are found in increased numbers in hypercholesterolemic mice and neutrophil depletion effectively reduces atherosclerosis if neutrophil-depleting antibodies are administered during early atherosclerosis development (16, 17) . A concept has been put forth where neutrophils pave the way for monocyte infiltration during early atherosclerosis development (18) . Platelets also assist in the recruitment of immune cells to the atherosclerotic plaque by facilitating interactions between endothelial cells and monocytes, neutrophils, dendritic cells and T cells (19) . T cell responses have generally been regarded as pro-atherogenic, although protective T cell responses also exist.
In this context it is interesting to note that cardiovascular complications are more common in human immunodeficiency virus-infected individuals than in age-matched uninfected individuals and that antiretroviral therapy, which increases T cell counts, reduces the cardiovascular risk in treated subjects (20) .
T cells modulate inflammation in atherosclerosis
Initial studies in severely immune-deficient mice provided inconclusive and partly contradictive findings regarding the role of the immune system in atherosclerosis (21) (22) (23) . It was later revealed that this was explained by the fact that both protective and atherogenic immune responses exist (24) . There is now convincing evidence that type 1 T helper (Th1) cells promote disease and deletion of the transcription factor T-bet, which is required for Th1 lineage commitment, reduces atherosclerosis (25, 26) . The role of type 2 T helper (Th2) cells in atherosclerosis is unclear as several Th2 cytokines have been assigned protective roles, whereas deletion of IL-4, the proteotypic cytokine for Th2 cells, reduces atherosclerosis development in some studies (27) (28) (29) .
The role of Th17 in atherosclerosis is also debated as conflicting reports exist (30) (31) (32) . In contrast to CD4 + T helper cells, CD8 + cytolytic T lymphocytes have not been extensively studied, even though CD8 + T cells are abundant in atherosclerotic plaques and they have been shown to be activated in hypercholesterolemic Apoe -/-mice (33) . Activation of CD8 + T cells has also been associated with increased plaque formation in these mice (34) . In apparent contrast with these observations, atherosclerosis protection achieved by immunization with apolipoprotein B (apoB) peptide has been suggested to involve CD8 + T cells (35) . On the other hand, Tap1 
Emerging therapies promoting regulatory T cell responses
The with similar antigen specificity. However, it has been proposed that the balance between plaque antigen specific T effector cells and regulatory T cells is shifted in atherosclerosis allowing plaque inflammation to progress (10) . Accordingly, several novel strategies to promote peripheral tolerance against self-antigens in mice by modulating regulatory T cells have emerged and constitute an attractive novel approach to treat atherosclerosis. Particularly, the possibility to induce antigen-specific tolerance has advantages over more general anti-inflammatory therapies that also may compromise defence against invading pathogens. Autoimmunity against selfantigens, such as oxidized LDL and heat shock proteins (HSPs), play an important role in the development of atherosclerosis and immunization with HSPs or apoB peptides are associated with a decrease in atherosclerosis development (50, 51) . Atherosclerosis protection achieved by immunization with apoB peptide and Alum adjuvant has been credited to regulatory T cell dependent mechanisms (52, 53) . Similarly, oral administration of oxidized LDL or HSP60 is associated with increased number of regulatory T cells and reduced atherosclerosis (46, 54) .
Mucosal delivery of apoB peptides has also been shown to reduce atherosclerosis and to be associated with an increase in Tr1-type regulatory T cells (47) . Furthermore, subcutaneous infusion of low doses of apoB peptide has been shown to inhibit atherosclerosis development and was found to promote antigen-specific regulatory T cells (55) . Dendritic cells can also be used to confer tolerance to self-antigens. Intravenous administration of dendritic cells pulsed with the complete apoB protein and IL-10 reduces atherosclerosis by a mechanism involving activation of regulatory T cells (56) . Taken together, these data imply that immunizations with self-antigens boosts existing regulatory T cell immunity and that breaking the tolerance to self-antigens may be an important contributor to atherosclerosis development (49, 57) . The first of these therapies are now close to entering clinical testing, emphasizing the need for a better understanding of the role of regulatory T cells in cardiovascular disease in humans. Based on the experimental evidence both oxidized LDL and more well defined LDL antigens, such as different apoB peptides, represent possible components of future atherosclerosis vaccines for human use ( shown that the accumulation of Ly-6C high monocytes is accelerated in the aorta of mice subjected to a myocardial infarction by coronary ligation (87) . These data indicate that myocardial infarction might be followed by a period of increased plaque growth and vulnerability fuelled by increased monocyte inflammation, which may explain the high risk of recurring events in acute coronary syndrome patients, if monocyte behaviour is similar in humans.
Therapeutic opportunities to target chemokine receptors and monocytes
In humans at least three monocyte subsets can be defined by their expression of CD14 and CD16 (88 inflammation that weakens the fibrous cap covering plaques and thus be associated with increased risk of clinical events, whereas CD16-expressing monocytes might play a role in determining the size of the plaque, perhaps even having a protective, or reparative, rather than plaque promoting function.
Despite strong evidence in mice, Berg et al. found no association between CX3CR1 and CCR2 expression on monocytes and cardiovascular risk (89) . CCR5 expression on non-classical CD14 + CD16 ++ monocytes was, however, negatively associated to carotid IMT. Although the association of chemokine receptor expression on monocytes to cardiovascular risk is poorly understood, the potential to treat human disease by targeting chemokine receptors is emphasized by the fact that polymorphisms in the CX3CR1 gene have been found to protect against atherosclerosis (90) (91) (92) . Evidence also indicate that a naturally occurring frame-shift mutation in the human CCR5 gene is associated with lower carotid intima-media thickness in the common carotid artery and reduced cardiovascular disease risk (93) . Also, in mice, pharmacological intervention of several chemokine receptors has been proven to reduce atherosclerosis (94) . In addition, it has been speculated that several approved chemokine receptor antagonists, such as CCR5 antagonists approved for HIV therapy, could also limit plaque development (95) . At present, clinical studies targeting atherosclerosis with these compounds have, however, not been initiated.
Anti-inflammatory drugs and atherosclerosis
The fact that atherosclerosis is an inflammatory disease taken together with observations that inflammatory biomarkers such as CRP predicts risk for cardiovascular events (96) suggests the possibility of using anti-inflammatory drugs in prevention and treatment of the disease.
However, in conflict with this notion the use of non-steroidal anti-inflammatory drugs (NSAID)
has been found to be associated with increased cardiovascular risk (8, 9) . Statins, on the other hydrolysed by Lp-PLA2 to generate pro-inflammatory lysophosphatidylcholines (lysoPCs) (101) and recent studies have revealed very strong association between the levels of lysoPC and proinflammatory cytokines in human atherosclerotic plaques (102) . Plasma levels of Lp-PLA2 and its activity have also been shown to be independent predictors of cardiovascular risk in several epidemiological studies (103) . Darapladib is currently being studied in two large phase III trials: which is estimated to include 11,500 patients with acute coronary syndromes.
Challenges facing the translation of experimental immune-modulation of atherosclerosis into clinical therapy
Current therapies focusing on risk factor reduction such as lipid-lowering treatment have been shown to reduce the risk of ischemic cardiovascular events by up to 40% in randomized clinical trials (1). However, it is difficult to achieve additional risk reduction by treating risk factors alone leaving the majority of treated subjects without sufficient protection emphasizing the need for development of novel therapies directly targeting the atherosclerotic disease process in the plaque. Such therapies should preferentially act through specific inhibition of plaque inflammation. Down-regulation of pro-inflammatory autoimmune response against plaque antigens represents a potential approach to achieve this. As discussed above several tolerogenic plaque-antigen vaccines have been shown to be effective in animal models of atherosclerosis.
However, the challenge of translating these results into clinically effective therapies should not be underestimated. Most of the available knowledge of the role of immunity in atherosclerosis is based on studies performed in mice and our understanding of the importance of these disease mechanisms in humans remains limited. There is an urgent need for studies identifying and validating immune biomarkers for cardiovascular risk in man as well as to develop biomarkers that can be used to monitor the effect of atherosclerosis vaccines in clinical trials. Such biomarkers are likely to include plaque antigen-specific autoantibodies, antibodies against vaccine antigens and detailed characterization of circulating immune cells believed to be involved in the disease process. To obtain sufficient sensitivity these biomarkers also needs to be antigen specific. Although the key antigens in human atherosclerosis need to be more firmly established it will be relatively straight-forward to develop and standardize assays for determination of autoantibodies against these antigens. The same will most likely be true for vaccine antigens. However, the experience from animal studies suggests that the mechanism of action of athero-protective immune therapies involves modulation of cellular immunity that may be equally or more important than modulation of humoral immunity. Characterization of different T cells, such as Th1 and regulatory T cells using flow cytometry is relatively simple in the young genetically identical mice with limited exposure to pathogens used in experimental atherosclerosis studies. However, this is considerably more difficult in a clinical setting where the different T cell populations are much more heterogeneous. Such analysis should preferably also be done in an antigen-specific way, e.g. it should be possible to restrict the analysis to T cells specific for a certain atherosclerosis or vaccine antigens. Possible approaches to achieve this include ex vivo antigen challenge and the use of synthetic tetramer HLA-antigen constructs that binds only to T cells specific for that antigen. Important immune targets for monitoring disease and the efficacy of immune-modulatory therapies are summarized in Figure 2 .
Another important limitation of the animal studies is that they with few exceptions have demonstrated effect of vaccines on early development of atherosclerosis rather than on the more clinically relevant advanced plaques. It is not unlikely that strategies for immune-modulatory therapy targeting advanced established plaques need to be different from those aiming to prevent early stages of disease. In this context it is encouraging to note that Herbin et al. (55) were able to completely halt the progression of advanced atherosclerosis by subcutaneous infusion of apo B peptides.
The clinical development of an immune-modulatory therapy for atherosclerosis also faces several regulatory challenges. If shown to be effective this type therapy could potentially be widely used even in subjects without clinically manifest disease. Accordingly safety standards must be very strict. The potential side effects include general immune suppression increasing the risk for infections as well as activation of immune process with adverse effects on the atherosclerotic disease process. Possible adverse side effects of an immune-modulatory therapy are likely to be closely related to its mode of action. Accordingly, it is essential to characterize the exact mechanisms through which such a therapy works not only in experimental animals but also in humans. 
Conclusions and perspectives

